<DOC>
	<DOC>NCT01067118</DOC>
	<brief_summary>The purpose of this study is to determine if the use of Linjeta(tm) insulin when compared to Humalog will result in significantly lower episodes of hyperglycemia and hypoglycemia after a breakfast meal.</brief_summary>
	<brief_title>A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin, Short-Acting</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>1)Type 1 diabetes for at least 1 year 1. The diagnosis of type 1 diabetes is based on the investigator¡s judgment; C peptide level and antibody determinations are not needed. 2) Age : 18 years old ¨C 49.99 years old 3) Continuous subcutaneous insulin infusion (CSII) therapy for at least 3 months 4) Participant consent demonstrated by signing IRB approved documents 6) HgA1c ¡Ü 9% 7) If participant is female with reproductive potential, willing to avoid pregnancy and pregnancy test negative. 1) Chronic oral steroid use 2) The presence of a significant medical disorder that in the judgment of the investigator will affect the wearing of sensors or the completion of any aspect of the protocol. 3) Known clinical history of celiac disease or inflammatory bowel disease. 4) Participants will have a negative antiendomysial antibody or antitissue transglutaminase antibody within one year of enrollment. 5) Cystic Fibrosis 6) Inpatient psychiatric treatment in the past 6 months. 7) Currently pregnant or lactating, or anticipate getting pregnant in the next one year. 8) Clinical diagnosis of gastroparesis. 9) Insulin binding capacity greater than 10 microunits per litter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>